We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Selvita Sa | LSE:0RKT | London | Ordinary Share | PLSELVT00013 | SELVITA ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 67.99M | -92.11M | -3.9841 | -14.31 | 1.32B |
KRAKOW, Poland, May 13, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that the company will present at the UBS Global Healthcare Conference, taking place on May 20-22 in New York. Chief Executive Officer Pawel Przewiezlikowski is scheduled to present a corporate overview on Tuesday, May 21 at 3:30 p.m. EDT.
Selvita will be also present at Jefferies 2019 Healthcare Conference, taking place on June 4-7, in New York, NY, USA.
About Selvita
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K. In March 2019, Selvita announced the intent to split its oncology development and research services divisions into separate companies.
Contact:
Julia Balanova (investors)
+1 646 378 2936
jbalanova@troutgroup.com
Rich Allan (media)
+1 646 378 2958
rallan@troutgroup.com
Natalia Baranowska (corporate)
+48 784 069 418
natalia.baranowska@selvita.com
View original content:http://www.prnewswire.com/news-releases/selvita-to-present-at-the-ubs-2019-global-healthcare-conference-in-new-york-300848688.html
SOURCE Selvita
Copyright 2019 PR Newswire
1 Year Selvita Chart |
1 Month Selvita Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions